Quiet on the insider front: nobody at Cyclacel Pharmaceuticals, Inc. bought or sold CYCC shares with their own money this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
Quiet on the insider front: nobody at Cyclacel Pharmaceuticals, Inc. bought or sold CYCC shares with their own money this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Kua Khai Loon | 10% Owner | Sell | 19,054 | $7.01 | $134K | SEC |
| Aug 4, 2025 | Lazar David E. | 10% Owner | Sell | 6,750 | $12.36 | $83K | SEC |
| Feb 28, 2025 | Lazar David E. | CEO | Sell | 194,628,820 | $0.03 | $5.8M | SEC |
| Dec 26, 2023 | McBarron Paul | Officer | Buy | 1,886 | $3.32 | $6K | SEC |
| Dec 26, 2023 | Rombotis Spiro George | CEO | Buy | 6,070 | $3.32 | $20K | SEC |
There were no open-market insider trades in CYCC in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in CYCC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).